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ABSTRACT   64 
Adverse drug reactions (ADRs) are the unintended side effects of drugs. They are categorised as 65 
either predictable or unpredictable drug-induced injury and may be exhibited after a single or 66 
prolonged exposure to one or multiple compounds. Historically, toxicology studies rely heavily on 67 
animal models to understand and characterise toxicity of novel compounds. However, animal 68 
models are imperfect proxies for human toxicity and there have been several high-profile cases of 69 
failure of animal models to predict human toxicity e.g. fialuridine, TGN1412 which highlight the need 70 
for improved predictive models of human toxicity. As a result, stem cell derived models are under 71 
investigation as potential models for toxicity during early stages of drug development. Stem cells 72 
retain the genotype of the individual from which they were derived, offering the opportunity to 73 
model the reproducibility of rare phenotypes in vitro.   74 
Differentiated 2D stem cell cultures have been investigated as models of hepato- and cardiotoxicity. 75 
However, insufficient maturity, particularly in the case of hepatocyte-like cells, means that their 76 
widespread use is not currently a feasible method to tackle the complex issues of off target and 77 
often unpredictable toxicity of novel compounds. This review discusses the current state of the art 78 
for modelling clinically relevant toxicities, e.g., cardio- and hepatotoxicity, alongside the emerging 79 
need for modelling gastro-intestinal toxicity and seeks to address whether stem cell technologies are 80 
a potential solution to increase the accuracy of ADR predictivity in humans.  81 
INTRODUCTION   82 
Adverse drug reactions (ADRs) are the harmful side effects of medicine which may occur after acute 83 
or chronic exposure to a compound. They place a significant financial burden on the healthcare 84 
industry and contribute to approximately 5% of all hospital admissions [1]. Similarly, ADRs are 85 
burdensome to pharma, who face financial loss due to drug withdrawal if toxicity is detected post-86 
marketing. The current cost of developing a drug is $648 million USD over 10-15 years [2], which is a 87 
major concern given that many drugs do not exhibit ADRs until late stage trials when large 88 
investments of time and money have already been made. Between 1980 and 2009, 15% of licenced 89 
drugs having proven efficacious in phase II trials, were terminated with the main reasons being 90 
unanticipated cardiotoxicity, hepatotoxicity and gastrointestinal (GI) toxicity [3]. Currently, cardiac 91 
drug-induced injury is the leading cause of drug withdrawal, whilst drug induced liver injury is the 2nd 92 
leading cause of drug termination and causes approximately 50% of acute liver failure [4]. 93 
Unpredicted cardiotoxicity is the main reason for drug termination, accounting for 28% of drug 94 
withdrawals [5]. In the USA, the gastrointestinal tract has been associated with 20% of drug-induced 95 
events [6].  96 
Human embryonic stem cells (ESCs) were initially discovered in blastocyst stage embryos, whilst 97 
induced pluripotent stem cells (iPSCs) were developed approximately 13 years ago,  by 98 
reprogramming adult somatic cells by overexpression of the Yamanaka factors: Oct4, Sox2, Klf4 and 99 
cMyc (OSKM) [7]. Both ESCs and iPSCs are pluripotent, meaning that they can differentiate into any 100 
somatic cell type. IPSCs can be derived from individuals known to have unusual or diseased 101 
phenotypes, these phenotypes can then be introduced into in vitro assays at early stages during 102 
toxicity testing. Genetic modification platforms such as CRISPR-Cas9 can be utilised to generate 103 
isogenic human iPSC lines that can be used to assess cross-organ ADR responses from the same 104 
patient. The process for deriving iPSCs is minimally invasive requiring only a skin biopsy or blood 105 
sample, though any tissue type can be used.   106 
Stem cells are able to be exploited in both 2D and 3D, therefore utilising spheroids and organoids to 107 
model in vivo systems. Spheroids are self-aggregating clusters of cells that form spontaneously when 108 
adherent cells are denied an attachment surface. Spheroids have been observed for almost as long 109 
as cell culture has been practiced with observations of cells ‘rounding off into little spheres’ as early 110 
as 1907 [8]. Due to their 3D physiology, spheroids can be used to replicate a 3D microenvironment 111 
which is thought to improve the relevance of cell models to organ parenchyma. Despite their 112 
advantages over monolayer systems, spheroids are not perfect as they are typically hypoxic above a 113 
given size due to the diffusion gradient of oxygen through non-vascularised tissue, which often leads 114 
to necrosis in the core. Despite hypoxia being observed in spheroids, most 2D and 3D cultures are 115 
said to be in hyperoxic conditions (21% O2), which causes hepatocyte dedifferentiation and therefore 116 
a loss of specific cell functions. Notably, 5% O2 is very effective in maintaining epithelial morphology 117 
and retain hepatic functions for up to 5 days [9]. Due to their necrotic core, spheroids can be 118 
alternatively used to model small tumour growth, as angiogenesis has not yet occurred in vivo and 119 
accurately models an oxygen gradient in a tumour microenvironment. Generally, spheroids are 120 
comprised of a single cell/tumour cell type. Whilst spheroids are useful in modelling 3D culture, due 121 
to their necrotic core and lack of vasculature, spheroids can be used to model tumour growth. Whilst 122 
in vitro cultures are not entirely representative of normal tissue, mixed populations of non-123 
transformed cells are possible, as is layering with multiple cell types to recapitulate organ structure. 124 
Crucially, spheroids do not spontaneously form organotypic structures or differentiate into more 125 
mature tissues.  126 
Organoids are a 3D heterogeneous collection of cells, self-organising to recreate organ 127 
microanatomy. Organoids self-arrange with a central lumen, allowing for more complete drug 128 
penetration and the establishment of a toxicological gradient. Organoids are often derived from 129 
tissue resident stem cells, thus making biopsy of the target tissue necessary. This has several 130 
disadvantages compared with iPSC-derived models which can be derived from easily accessible cells 131 
[10], including collection time, patient consent and the volume of culture material. However, 132 
organoids remain a promising nascent model for examining toxicity in multiple tissue types. 133 
Moreover, some studies have shown that organoids may be produced from iPSCs and exhibit the 134 
phenotype of the patient overcoming this limitation of organoid culture [11].  A study conducted by 135 
the Clevers group, has demonstrated that hepatic organoids express a similar level of CYP3A4 136 
compared to freshly isolated hepatocytes, and was verified via midazolam metabolism. This study 137 
highlighted the potential of hepatic organoids, replicating a clinical level of metabolism, whilst 138 
adopting key 3D functions to mimic an in vivo system [12]. 139 
 140 
Hepatotoxicity 141 
The liver is the major site of metabolism and detoxification of xenobiotic compounds, which leads to 142 
high incidences of ADRs, therefore hepatoxicity is a leading cause of attrition in drug development. 143 
Human primary hepatocytes (hPH) are considered the gold standard for studying in vitro 144 
hepatotoxicity though they are not a flawless model. A major limitation of using mature hPH is that 145 
they rapidly de-differentiate immediately after the tissue is removed from the patient’s blood supply 146 
and continue to de-differentiate over approximately one-week post-isolation in culture [13]. 147 
Moreover, de-differentiation causes a large reduction in expression of key hepatic proteins, e.g. 148 
cytochromes P450 and other key phase I/II enzymes and transporters, which directly affect drug 149 
metabolism and therefore the validity of the cell model.   150 
To overcome the limitations of hPH stability in vitro, a more physiologically relevant and stable 151 
model is required to measure the long-term effects of drug induced toxicity. Immortalised cell lines, 152 
such as HepG2 and HepaRG cells can be used, primarily due to their highly proliferative nature and 153 
ease of culture. However, these cell lines are far less physiologically relevant compared to hPHs 154 
often lacking many key hepatic proteins. iPSC-derived hepatocyte-like cells (iPSCHLCs) are a potential 155 
‘Goldilocks’ model combining the replicative nature of cell lines with the potential for close 156 
physiological relevance offered by primary cells. They are also able to maintain the phenotype of a 157 
single donor allowing repeat experiments under similar genetic conditions, something that is 158 
typically not possible with primary cells. Despite their promise, iPSCHLCs do not currently fully 159 
recapitulate the phenotype of freshly-isolated hPHs, and, like hPH, do not proliferate when 160 
differentiated. However, only a few phenotypic markers are used, which suggests an inadequate 161 
benchmark for hepatocyte phenotyping [3].   162 
The phenotype of hepatic models can be examined using drugs previously known to be metabolised 163 
by specific enzymes. Several key drugs were analysed, namely, phenacetin (CYP1A2), diclofenac 164 
(CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6) and midazolam (CYP3A4) [14]. HepaRG and 165 
iPSC-HLCs displayed similar metabolic rates after 8 days, except in the case of CYP3A4 dependant 166 
metabolism, where iPSC-HLCs showed substantially higher metabolism (Table 1). The iPSCHLCs 167 
demonstrated stable metabolic rates of all tested cytochromes P450 until day 29, except for CYP3A4 168 
which showed a sharp decrease to levels similar to those observed in HepaRG cells at day 9 (Table 1).  169 
IPSC-HLCs have shown early success in safety assessments, particularly with regard to their ability to 170 
reproducibly model diseased phenotypes. High throughput screening is widely applied in drug 171 
development to prioritise lead molecules, to decrease animal use [15], allowing for Tox21/ToxCast 172 
programs to aid decision making [16] during drug discovery. The necessity to generate data on the 173 
potential toxicity of at least 30’000 compounds, is expected to require up to 10 million animals [17]. 174 
In one study, iPSCs were derived from patients with α1antitrypsin (A1AT) deficiency [18], and 175 
through high-throughput screening, a compound that significantly reduced defective A1AT within 176 
the cytoplasm was identified [19]. As a result, iPSCs from diseased donors are being investigated for 177 
other conditions, including: hypercholesterolemia [20], glycogen storage disease [20-23], Gaucher’s 178 
disease [24], hereditary tyrosinemia [20], hereditary cholestasis [18] and defective mitochondrial 179 
respiratory chain complex disorder [23].   180 
Human skin-derived precursors (hSKP) are a multipotent stem cell line that can be differentiated 181 
towards a hepatic fate (hSKP-HPC). The response of hSKP-HPC to paracetamol (APAP) was recently 182 
examined using qPCR analysis [25]. Notably, CYP3A5, a foetal isoform of CYP3A4, demonstrated a 183 
15-fold increase in hSKP-HPC upon APAP exposure demonstrating the capacity for induction of key 184 
metabolic enzymes in these cells [20]. Basal levels of several CYPs in hSKP-HPC have been found to 185 
be minimal [26], however, it has been hypothesised that the CYP expression may fluctuate 186 
depending on the xenobiotic to which they are exposed.   187 
Like most cells, stem cells are currently most commonly cultured in 2D conditions. This is a major 188 
limitation, since these models cannot completely mimic the physiology of an in vivo system e.g. no 189 
connective tissue or presence of extracellular matrix. 2D systems have contributed to a poor 190 
standard of pre-clinical in vitro hepatotoxicity assays. Consequently, more than 90% of drugs that 191 
yield positive data during in vitro preclinical studies fail the safety margins required in subsequent 192 
clinical trials. As a result of a lack of key phenotypic properties in 2D models, 3D models are currently 193 
being explored to improve the reliability of in vitro toxicity assays [26].   194 
HepG2 cells in a typical rigid 3D culture show improved hepatic functions over monolayer cultures in 195 
terms of glycogen storage, bile salt transportation, development of bile canaliculi and increased 196 
expression of CYP3A4, CYP2E1, CYP2C9, CYP2C19, CYP2D6 and UGT1A1 [26]. Drug-induced 197 
cholestasis (DIC) is measured in vitro by the compound’s ability to inhibit bile salt export pump 198 
(BSEP), however, DIC is typically complex, multifactorial and delayed in its manifestation [27-29], and 199 
therefore innovative toxicity models are required. Spheroid models formed via hPH and HepaRG 200 
cells were dosed with a cholestatic inducing compound; chlorpromazine [30]. Both models displayed 201 
DIC related toxicity, whilst the HepaRG spheroid also displayed reduced F-actin expression, 202 
indicating chlorpromazine in disrupting structural integrity, which has been implicated in early 203 
chlorpromazine-induced cholestasis through oxidative stress [31].   204 
Organoid models are being developed in the hope that they will improve upon current 3D models. 205 
When compared to human foetal liver progenitor cell derived hepatocytes (hFLPC-HLCs) human liver 206 
organoids showed far greater urea and albumin production. After 21 days human liver organoids 207 
produced approximately 4.4-fold higher albumin concentrations and 4.0-fold higher urea 208 
concentrations than hFLPC-HLCs. These results show that organoids are potentially capable of 209 
greater physiological relevance than traditional 2D culture systems [32]. It has been suggested that 210 
isolated primary hepatocytes can be used to generate branched hepatocyte-like organoids (Hep-211 
Org), when exposed to a variety of small molecules, including RSPO-1 and other Wnt agonists [33]. 212 
Through biliary ductal cell isolation, it is possible to generate cholangiocyte-like organoids (Chol-213 
Org), which differ greatly from Hep-Org, as shown through RNA analysis, and through lineage 214 
tracing, loosely indicates a similarity between primary hepatocytes and Hep-Org, however, Hep-Orgs 215 
have shown decreased HNF4a and albumin expression, 2 & 4-fold decrease respectively, whilst Chol-216 
Orgs demonstrated >1000-fold decrease [33]. Notably, genes involved in hepatocyte functions such 217 
as cytochrome P450 activity, glycogen metabolism, lipid metabolism, steroid metabolism, urea cycle 218 
and complement activation all displayed very similar expression profiles between Hep-Orgs and 219 
primary hepatocytes [33]. 220 
CARDIOTOXICITY   221 
IPSC-derived cardiomyocytes (iPSC-CM) have great potential in cardiotoxicity research. They offer an 222 
attractive platform to mimic cardiovascular diseases, model early stages of cardiac development and 223 
advance predictive toxicology assays in vitro. Like other iPSC-derived models iPSC-CMs retain the 224 
donor phenotype potentially allowing multiple experiments on rare phenotypes and have been used 225 
to model complex channelopathies such as prolonged QT syndrome, catecholaminergic polymorphic 226 
ventricular tachycardia and familial hypertrophic cardiomyopathy [34-36], alongside those seen in 227 
table 2. The predictive capability of iPSC-CMs is therefore dependent on key structural 228 
characteristics and electrophysiology in vitro.  229 
A key benefit to using iPSC-CMs is phenotypic retention, which is the ability to model drug induced 230 
cardiotoxicity in diseased states. Cardiomyocytes were dosed with 1-300 nM of Cisapride, a potent 231 
HERG channel blocker, using control human embryonic stem cells (hESC-CMs) and hESC-CMs from 232 
long QT syndrome (LQT), hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) 233 
patient-derived cardiomyocytes (table 2). Cisapride was observed to provoke early 234 
afterdepolarisation (EAD) at different concentrations for each diseased cell type [37]. Nicorandil, a 235 
K+ channel opener, was next applied to elicit drug-induced responses in disease cell models. 236 
Nicorandil has been implicated in shortening the QT interval through increased K+ efflux, therefore 237 
inducing arrhythmias [38-40]. Upon Nicorandil application to diseased cardiomyocytes, 100 nM was 238 
found to both normalise APD prolongation and remove spontaneously occurring EADs. Many studies 239 
also reported arrhythmia induction in patients receiving high levels of Nicorandil due to excessive QT 240 
shortening [41-43]. Several key disease phenotypes have also been modelled (table 2), with 241 
successful toxicology studies performed.     242 
In a recent study, embryonic stem cell derived-CMs (ESC-CMs), were exposed to a range of cadmium 243 
chloride (CdCl2) concentrations to induce morphological changes. Consistent with previous studies, 244 
significantly higher levels of reactive oxygen species (ROS) were observed in CdCl2 treated cells 245 
compared to control [44-46]. In addition, ESC-CMs displayed sarcomeric disorganisation and 246 
disruption, increased nucleoplasmic ratio and nuclear membrane shrinkage [47]. These results are in 247 
concordance with in vivo studies, in which CdCl2 disrupts cardiac structure and integrity. These 248 
results show that ESC-CMs can recapitulate complex cardiac structure and electrophysiology, which 249 
is important for accurate prediction of cardiotoxicity.   250 
A critical function of cardiomyocytes is their contractile ability, therefore the effects of E-4031 (a 251 
class III antiarrhythmic compound) was considered to examine antiarrhythmic effects. 252 
Administration of E-4031 at 30-100nM, resulted in a significant decrease in beating rate (32.7 253 
±1.2/min) vs vehicle control and a decrease in contractile velocity vs vehicle control [48]. The recent 254 
work of the Wu group is an important advance as it shows that even for a complex, off-target 255 
toxicity such as doxorubicin-induced cardiotoxicity, which likely entails decreased mitochondrial 256 
function, perturbed calcium regulation and oxidative stress, it is possible to emulate this using 257 
patient-derived single cell iPSC-cardiomyocytes [49]. A critical function of cardiomyocytes is their 258 
contractile ability, therefore the antiarrhythmic effects of E-4031(a class III antiarrhythmic 259 
compound) were examined. Administration of E-4031 significantly decreased contractile velocity and 260 
beating rate in iPSC-CTs (32.7 ±1.2/min) [48]. Dose-dependent doxorubicin toxicity has been 261 
successfully modelled in iPSC-CTs, reporting the reported minimum effective concentration of 262 
doxorubicin in monolayer iPSC-CM systems is not significantly different from the concentrations 263 
achieved in pre-clinical studies, therefore indicating a comparable tolerance to cytotoxins between 264 
systems [48], [50-52]. 265 
A recent study treated cardiomyocyte spheroids with antibiotic, antidiabetic and anticancer drugs 266 
[52] The spheroids showed physiologically relevant structure and metabolic functions, as 6/8 known 267 
cardiotoxic compounds tested were also detected in vitro, therefore, CM spheroids correctly 268 
identified 75% of cardiotoxic compounds, compared to clinical data. The study has found 3D cardiac 269 
tissue models tested in this manner are more sensitive to cardiotoxicity than traditional viability 270 
assays. Another recent study has reported that rosiglitazone; a potent antidiabetic drug, induced 271 
severe contractile failures in mice at 10-30 μM [53], when iPSC-CM derived spheroids were treated 272 
in a similar manner, the microtissue stopped contracting at 50 µM. This study suggests that 273 
spheroids are not currently as sensitive as an in vivo model, and whilst they are not a perfect model, 274 
they can exhibit physiological changes in response to an insult. Spheroids exhibit action potential 275 
propagation, force transduction and contractile tension, which play a critical role in 276 
pharmacologically induced responses of cardiomyocytes and show increased expression of cardiac 277 
troponin (cTnT) and aMHC [54-56].   278 
There are, however, shortcomings with iPSC-CMs which must be overcome to establish a reliable in 279 
vitro model. The maturity of iPSC-CMs must be improved to establish predictive electrical, 280 
mechanical and metabolic function. Stem cell differentiation protocols can lead to variability, 281 
depending on the protocol used. This can lead to differences in phenotype and variation in the 282 
proportion of cell types produced, e.g. atrial-like cells or pacemaker-like cells. A common problem 283 
with 3D cardiomyocytes is the extra-cellular matrix effecting the contraction and relaxation of the 284 
system which may restrict the ability to contract due to the attachment to a rigid matrix. To negate 285 
the effect of a matrix upon 3D-CM’s, it is possible to generate ‘free-floating’ spheroid like structures, 286 
e.g., hanging droplet formation, which display beating cardiomyocytes. 287 
GASTROINTESTINAL TOXICITY   288 
The gastrointestinal (GI) tract plays an important role in xenobiotic bio activation, metabolism and 289 
detoxification, as it is enriched with xenobiotic processing proteins. The epithelium of the GI tract 290 
has a rapid cell turnover, involving the proliferation of stem cells at the base of the crypt which 291 
produce daughter cells that then migrate along the crypt-villus axis. Intestinal stem cells either divide 292 
asymmetrically, which leads to one identical daughter stem cell and one transit amplifying cell that 293 
initially retains some proliferative capacity, but eventually becomes a committed progenitor. Rarely, 294 
stem cells divide symmetrically giving rise to two stem cells. The Wnt target gene leucine rich-295 
repeat-containing G-protein coupled receptor 5 (LGR5) [57] is expressed in cells found at the base of 296 
a crypt and is widely believed to label active cycling stem cells. Lineage tracing using LGR5 has shown 297 
that all five differentiated intestinal epithelial cells arise from these stem cells: columnar epithelium 298 
(mainly absorptive enterocytes), goblet cells, Paneth cells, tuft cells and neuroendocrine cells [58]. 299 
LGR5 positive cells are located at the base of small intestinal and colonic crypts in crypt base 300 
columnar cells, which are thought to be active adult intestinal stem cells [11] and self-renew with an 301 
approximately 24-hour cell cycle time [59]. Therefore, LGR5 detection would allow for efficient 302 
characterisation of adult stem cells in vitro. Whilst adult stem cells are source-limited in comparison 303 
to iPSC enteroids, they enable spontaneous formation of organoid structures, maintaining any 304 
genetic mutations to model disease states. Also, tissue-derived organoids can be generated more 305 
cheaply and with greater efficiency than iPSC enteroids, since differentiation is not required. 306 
GI organoids are well established, characterised and have a relatable metabolic profile compared to 307 
donor matched tissue [58]. GI organoids are generated via stem cell isolation from the intestinal 308 
crypt [60]. Crypt cultures form spherical structures almost immediately, with small buds appearing 309 
typically after 5 days [11]. Human-derived GI organoids require culture in differentiation medium to 310 
generate all mature cell lineages [61] and there are subtle differences in growth medium and 311 
dynamics between small intestinal-derived enteroids and colon-derived colonoids [62]. Multiple 312 
phase I/II drug metabolising enzymes and transporters have been identified in enteroids [10]. Stable 313 
crypt cultures express high levels of CES1/2, UTG1A1 and key drug transporters ABCC2 & ABCB1A 314 
[63]. 315 
  316 
Irinotecan is a potent anti-cancer drug, which upon hydrolysation by carboxylesterases (CES) forms 317 
the active topoisomerase inhibitor SN-38, which undergoes glucuronidation by UGT1A1 to form 318 
SN38G. Cytochrome P450 3A4 (CYP3A4), is one of the most versatile drug metabolising enzymes, 319 
accounting for the metabolism of approximately half of all prescribed medications [64] and is 320 
responsible for hepatic metabolism of irinotecan. Typically, the bio activation and detoxification of 321 
SN-38 has been accredited to hepatic pathways [63], through CYP3A4 metabolism, though CYP3A4 is 322 
also present in the GI tract. However, recent studies using gastrointestinal organoids have implicated 323 
intestinal CES2 with a greater affinity for irinotecan metabolism than hepatic CES1 [59]. GI organoid 324 
mediated irinotecan metabolism can be measured via intra/extra-cellular concentrations of 325 
irinotecan/SN-38/SN-38G and can be used to quantify bio activation and detoxification using 326 
HPLCMS analysis [65]. Further metabolic studies have shown that the presence of metabolites was 327 
detected in the extra-cellular medium, rising in concordance with irinotecan concentration. 328 
Intracellular SN-38 was significantly higher than SN-38G, which suggests significant efflux of SN-38G. 329 
GI organoids derived from UGT1A1 knockdown mice, retained their genotype and did not express 330 
UGT1A1, as a result, SN-38G was not detected [65].   331 
Intestinal organoids can replicate typical transport physiology, alongside host-pathogen interactions. 332 
Therefore, human intestinal organoids can be employed as a model to understand salt/water 333 
transport and diarrhoea-related pathophysiology. Human GI organoids have been shown to express 334 
sodium and chloride transporters (NHE3 and DRA respectively), chloride efflux channels (CFTR and 335 
BLM NCKCC1), sodium/potassium-ATPase and potassium channels [66].  336 
GI organoids are a useful model to create disease states in vitro, allowing for genetic and pathogenic 337 
influences to be analysed. Activation of cAMP signalling increases the membrane potential in wild 338 
type but not CFTR-/- murine organoids [67], upon treatment with forskolin, apical fluid secretion is 339 
observed, leading to intestinal cell shrinkage and organoid expansion allowing for a useful model to 340 
monitor intestinal CFTR-related fluid secretion [67, 68], which has enabled the development of a pre-341 
clinical screening assay to assess how patients respond to expensive cystic fibrosis drugs [69]. 342 
Diarrhoea, cholera, rotavirus and enterohaemorrhagic Escherichia coli (EHEC) are amongst the major 343 
causes of death worldwide [70]. Both cholera and rotavirus inhibit NHE3, by causing the GPCR to 344 
remain in an active state, leading to an increase in intracellular cyclic AMP which continually 345 
activates the CFTR [71]. Previous studies have also used iPSC-derived organoids in studying rotaviral 346 
infection [72]. Human intestinal organoids treated with a calcium/calmodulin kinase kinase 2 347 
inhibitor (STO-609) have been found to have significantly lower rotavirus infection, quantified by 348 
infectious virus particle production [66]. EHEC infection results in GI damage leading to 349 
micropinocytosis induction [72] which is indicative of symptoms found in vivo. IPSC-derived human 350 
intestinal organoids (HIO) exposed to a known antigen known to induce an identical response to 351 
EHEC, undergo large cytoskeletal changes, resembling micropinocytosis, highlighting the utility of GI 352 
organoids as an in vitro model [67].  353 
 354 
Human colonic organoids, isolated from healthy and adenocarcinoma tissue have been used to 355 
screen compounds, to establish their effect on patients with different genomes. Adenocarcinomic 356 
organoids derived from patients that exhibited a loss-of-function mutation in TP53 showed 357 
resistance to MDM2 inhibitor nutlin-3a, whilst ‘healthy’ organoids showed cell death. This has been 358 
further demonstrated when organoids from colonic tumours expressing KRAS mutations, exhibited a 359 
resistance to cetuximab (anti-EGFR inhibitor) [73]. Through genome sequence analysis, performed 360 
on organoids derived from a patient diagnosed with gastric cancer and metastasis, the presence of 361 
TFGBR2 was identified as a genetic factor for increased risk of metastasis [74]. Utilising CRISPR-Cas9, 362 
colorectal organoids can be effective in pre-clinical drug screening assays. In a KRAS wild-type colon 363 
tumouroid cell line that was sensitive to combinational therapy (EGFR and MEK inhibitors), the 364 
introduction of a KRASG12D mutation via CRISPR resulted in a loss of drug sensitivity. As the genetic 365 
makeup of these isogenic lines can be said to be identical before genome editing, this finding proved 366 
that it was indeed the RAS status of the tumour that was responsible for the loss of drug sensitivity. 367 
Therefore, CRISPR-guided genetic modification of organoids can serve to strengthen conclusions 368 
based on large drug screens [75], however, this technology is best served once the mechanism 369 
behind the disease is known. Modified isogenic cells provide little information in detecting ADRs that 370 
were not detected in humans during pre-clinical testing. Isogenic cells can however provide a very 371 
useful resource upon confirming a genetic disposition towards ADRs. 372 
CONCLUSION   373 
Patient-derived iPSC/hESCs can play a role in drug discovery and preclinical toxicity testing for the 374 
treatment of patients with gastrointestinal, cardiovascular, and liver diseases. Current drug testing 375 
platforms, such as animal studies and human clinical trials are not comprehensive, therefore human 376 
iPSCs may provide an advantage which can enhance the current approaches to drug toxicology 377 
studies. Moreover, the ability of human iPSCs to simulate organ systems in vitro may allow studying 378 
the effects of drug metabolites on various cell types. Many studies have utilised iPSC-based systems, 379 
in both 2D and 3D, to identify potential adverse drug reactions through disease modelling, 380 
metabolism studies and proteomic studies. Due to the phenotypic retention of iPSCs, efficiency of 381 
differentiation and epigenetic shadowing, disease states can be modelled, allowing for patient-382 
specific in vitro analysis. Whilst the application of iPSCs in toxicity testing and drug development 383 
represent a very advanced and practical use of stem cells, the acceptance and incorporation of the 384 
pharmaceutical industry to implement a new approach to current methods will be a slow process 385 
[76]. Whilst iPSC-derived hepatocytes are a valuable resource, they are not yet considered to be a 386 
‘perfect’ mature hepatocyte, which may limit their use in vitro, despite their many advantages: cost-387 
effectiveness, an unlimited source of hepatocytes, and the potential of high-throughput screening.   388 
Organoids are another promising model for in vitro toxicity, currently there are several issues 389 
preventing their widespread use. Organoids are fragile in culture since they rely on a gel-like scaffold 390 
of BME-2 or Matrigel to grow, limiting their scale up efforts. Another concern is that the organoid 391 
culture methodology is currently under patent, which may potentially limit their availability to be 392 
used commercially. With the current technology available, it is unlikely iPSC/ESC-derived systems 393 
and patient derived organoids are ready to replace animal models, this is mainly due to the 394 
complexity of recreating an in vivo system where every tissue is represented. Organoids cannot 395 
recreate a fully vascularised system and incorporate multiple cell types, e.g., macrophages and 396 
fibroblasts. In the future, we hope the field can advance in such a manner that allows for the co-397 
culture of organoids with other cell types whilst retaining a physiologically relevant structure. The 398 
flaws listed however are synonymous amongst most in vitro systems and not exclusive to stem cell 399 
systems. In conclusion, no current system can be said to be perfect, but due to the advantages and 400 
flexibility of stem cell systems, in both 2D and 3D, they are likely to be very useful to model toxicity 401 
in vitro, and in the future will feature more prominently in toxicity studies. In this review we have 402 
discussed how stem cell models as in vitro pre-clinical assays are rapidly evolving. These systems are 403 
sensitive to specific genome modification and the assessment of a patient’s susceptibility to a drug 404 
before clinical exposure. Rapid advancement of these systems to accurately predict patient 405 
response, particularly in the liver, heart and GI systems, will greatly accelerate the advancement of 406 
drugs from their development to clinical use, as these organs express the greatest abundance of key 407 
drug metabolising enzymes and consequently show the greatest susceptibility to ADR’s.  408 
 409 
Cell Model  Day   Cells per 
well 
x105  
 Drug Oxidation Activity 
pmol products/hour/1x105 cells  
    CYP1A2  CYP2C9  CYP2C19  CYP2D6   CYP3A4  
HepaRG   8   1.8   0.93±0.03  0.040±0.004  4.1±1.0  11±2.0   20±2.0  
iPSC #1   8   1.5   0.93±0.24   0.004±0.001   1.2±0.20   7.0±2.0   94±20.0  
29   1.1   1.2±0.10   0.053±0.006   7.9±0.80   24±4.0   26±2.0   
iPSC #2   8   1.5   0.78±0.19   0.002±0.0004   1.0±0.10   4.4±1.1   77±6.0   
29   1.3   1.2±0.10   0.027±0.005   6.5±0.70   16±1.0   24±3.0   
Table 1: Enzyme metabolic rates, depending on the concentration of product produced, comparing 410 
immortalised HepaRG cells against iPSC-Hep cell lines [14], showing the different systems responding 411 
to a known compound over 8 and 29 days. IPSCs responded in a far more stable manner over 29 412 
days, as HepaRG cells metabolic rates were too low to measure.   413 
   414 
Disease  Tested Drug(s)  
LQT1 Propanolol [77], isoprenaline [78]
LQT2 Nifedipine [38], propanolol [79], Allele specific siRNA [80], 
cisapride [81]  
LQT8  Roscovitine[39]  
CPTV1  Isoprenaline, forskolin [35]
DCM  Metoprolol, norepinephrine [82]  
HCM  Propanolol, verapamil, nifedipine [36]  
ARVC  Nifedipine [83], Isoproternol [84]  
Table 2 – Cardiac diseases which have been modelled in vitro using iPSC-CMs. Many drugs have been 415 
tested using disease state iPSC-CMs.   416 
  417 
 418 
 419 
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